Universal leukocyte reduction

Leukocyte reduction of blood components, in the United States, is generally reserved for conditions in which a clinical indication has been documented . There is no evidence that either Creutzfeldt-Jakob disease or variant Cre utzfeldt-Jakob disease are transmitted by transfusion in humans or that leu kocyte reduction of blood components could reduce their transmission. A num ber of adverse outcomes following transfusion are alleged to be the result of white blood cells. At this point in time, there are insufficient clinica l data to justify the universal leukocyte reduction of blood components, Cu rr Opin Hematol 2000, 7:397-401 (C) 2000 Lippincott Williams & Wilkins, Inc .